



*Small, but heading for the big time*

## **Nanobiotix receives US\$1m milestone payment from PharmaEngine**

*First patient injected with NBTXR3 in soft tissue sarcoma registration phase in Asia*

**Paris, France, Cambridge, MA, USA May 31, 2016 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205)**, a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, receives a US\$1m milestone payment from its Taiwan-based partner PharmaEngine.

The US\$1m payment from PharmaEngine has been triggered by the injection of the first patient undergoing treatment in Nanobiotix' Soft Tissue Sarcoma (STS) pivotal phase at a hospital in the Philippines.

### **About PharmaEngine and NBTXR3 development**

PharmaEngine has a licensing agreement with Nanobiotix for the development and commercialization of Nanobiotix's lead product, NBTXR3, in Asia-Pacific. As part of this agreement, Nanobiotix has already received upfront payments and milestone payments.

The Company is eligible to receive further development and commercialization milestone payments. Collectively, these payments may amount to a total of US\$56 million plus tiered, up to double-digit royalties on all net product sales in the Asian-Pacific region.

Beyond the Act.in.sarc study, PharmaEngine is also running a pilot phase (phase I/II) in rectal cancer, and is expected to expand its development to include new indications.

**-Ends-**

### **About NANOBIOTIX: [www.nanobiotix.com](http://www.nanobiotix.com)**

Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company's first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients.

NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration.

Nanobiotix's lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma, head and neck Cancer, prostate cancer, rectal cancer (PharmaEngine) and liver cancers (HCC and liver metastases). The Company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO:FP). The Company Headquarter is based in Paris, France. Affiliate in Cambridge, United States.

## Contact

---

Nanobiotix

---

**Sarah Gaubert**  
Head of Communication and Public Affairs  
+33 (0)1 40 26 07 55  
[contact@nanobiotix.com](mailto:contact@nanobiotix.com)



---

Media relations

---

France - **NewCap**  
**Annie-Florence Loyer**  
+33 (0)6 88 20 35 59  
[afloyer@newcap.fr](mailto:afloyer@newcap.fr)

Outside France - **Instinctif Partners**  
**Melanie Toyne Sewell**  
+44 (0) 207 457 2020  
[nanobiotix@instinctif.com](mailto:nanobiotix@instinctif.com)

## Disclaimer

*This press release contains certain forward-looking statements concerning Nanobiotix and its business. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix registered by the French Financial Markets Authority (Autorité des marchés financiers) on January 12, 2016 under number R.16-001 (a copy of which is available on [www.nanobiotix.com](http://www.nanobiotix.com)) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.*

*This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country.*